Chronic obstructive pulmonary disease (COPD) is underdiagnosed in the general population and possibly also in people living with HIV (PLWH). We evaluated the diagnostic performance of symptoms and risk factors for assessment of airflow limitation in PLWH and in uninfected controls.
Introduction
Chronic obstructive pulmonary disease (COPD) is a major global cause of morbidity and mortality [1] . Spirometry confirms the presence of chronic airflow limitation and is required to confirm the diagnosis [2] . We previously determined the prevalence of and risk factors for airflow limitation in people living with HIV (PLWH) and matched uninfected controls from the general population [3] . In that study, fewer than one-fifth of PLWH and uninfected controls with airflow limitation reported a previous diagnosis of COPD, suggesting that COPD was underdiagnosed in both groups. Previous studies conducted in the general population have also shown that COPD is universally underdiagnosed [4, 5] . Underdiagnoses may represent a missed opportunity to initiate adequate risk factor modifications and therapy.
The optimal approach for COPD case-finding in PLWH is unknown, but the European AIDS Clinical Society 2017 Guidelines advocate active case-finding [6] , that is, performing spirometry in individuals with respiratory symptoms and/or relevant exposures such as tobacco smoking, as opposed to routine screening with spirometry. These recommendations are in line with guidelines provided by the Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease (GOLD) 2017 Report, the UK National Screening Committee and the US Preventive Services Task Force (USPSTF) [2, 7, 8] .
In this study, we evaluated the diagnostic performance of respiratory risk factors and symptoms to detect spirometric airflow limitation in PLWH and uninfected controls.
Methods

Patients and results
The study design has been described elsewhere [3, 9] . PLWH and uninfected controls with spirometry from the Copenhagen Comorbidity in HIV Infection (COCOMO) study and Copenhagen General Population Study (CGPS), respectively, were recruited. Data collection for PLWH was performed at the Department of Infectious Diseases, Rigshospitalet, Copenhagen, and the Department of Infectious Diseases, Hvidovre Hospital, Copenhagen, between March 2015 and November 2016. Matched uninfected controls were recruited between January 2013 and December 2016 at Herlev Hospital, Copenhagen. The study was approved by the Regional Ethics Committee of Copenhagen (COCOMO: H-15017350; CGPS: H-KF-01-144/01). Written informed consent was obtained from all participants.
Spriometry
The EasyOne ultrasonic spirometer (ndd Medical, Z€ urich, Switzerland) was used in accordance with American Thoracic Society/European Respiratory Society guidelines. Lower limit of normal (LLN) (i.e. equivalent to -1.64 zscore) was calculated for pre-bronchodilator forced expiratory volume in 1 s (FEV 1 )/forced vital capacity (FVC) using multiethnic prediction equations provided by the Global Lung Function Initiative [10] . Airflow limitation was also defined by GOLD stage II disease, that is, FEV 1 / FVC < 0.7 and FEV 1 < 80% predicted [2] .
Data collection
Clinical information was obtained through self-report using identical questionnaires in PLWH and uninfected controls and included information about tobacco exposure and respiratory symptoms. Dyspnoea was defined by a modified British Medical Research Council (mMRC) scale ≥ 2 (scale 0-4). Chronic cough, sputum production and wheezing were defined by an affirmative response to the following questions: 'Do you have a cough lasting > 8 weeks?', 'Do you have a history of persistent sputum > 3 months per year?' and 'Do you occasionally have whistling or wheezing while breathing?', respectively. All individuals also reported whether they had previously been given a diagnosis of COPD by a health care professional.
Statistics
Uninfected controls were frequency matched with PLWH by sex and 5-year strata. As previously described, we were able to identify 14 unique uninfected controls per person living with HIV, but for men aged 30-35 years, it was only possible to identify three controls in each 5-year age interval [3] . Sensitivity, specificity, positive predictive values (PPVs), negative predictive values (NPVs) and area under the curve (AUC) were computed for all dichotomized predictors. We also computed the AUC and plotted the receiver operating characteristics (ROC) for the sum of five similar weighted items (i.e. age ≥ 50 years, wheezing, dyspnoea, sputum and packyears of smoking ≥ 20 years), as these were previously included in a questionnaire developed to identify individuals at risk of COPD for whom diagnostic evaluation was appropriate [11] . AUC was computed using the pROC package (v.1.10). As a sensitivity analysis, we redefined the criteria for airflow limitation to reflect GOLD stage II disease. Statistical analyses were performed in R (v.3.4.3) [12] .
Results
A total of 1083 PLWH and 12 074 uninfected controls were included in the study. The median age was 50.1 [interquartile range (IQR) 42.8-58.0] and 52.1 (IQR 45.5-60.9) years, 85.7 and 81.6% were male, and 29.2 and 12.9% were current smokers in PLWH and uninfected controls, respectively. In PLWH, the median CD4 count was 689 (IQR 520-889) cells/lL and 94.6% had suppression of HIV viral replication. Respiratory symptoms were more common in PLWH. Thus, as previously reported [3] , 7.8 versus 4.1% reported dyspnoea (P < 0.0001), 17.5 versus 9.5% reported sputum production (P < 0.0001), 12.9 versus 6.8% reported chronic cough (P < 0.0001) and 22.0 versus 15.8% reported wheezing (P < 0.001) in PLWH and uninfected controls, respectively. Table 1 depicts the diagnostic performance of a combination of different clinical characteristics (i.e. age ≥ 50 years, wheezing, dyspnoea, sputum production and cumulative duration of smoking ≥ 20 years). The sensitivity of these variables for detecting FEV 1 /FVC < LLN was generally better for PLWH than for uninfected controls. Sensitivity was highest for > 20 pack-years in both PLWH (56.1%) and uninfected controls (34.7%). Conversely, specificities seemed to be poorer in PLWH compared with uninfected controls. PPVs were largely similar between the groups and highest for self-reported COPD in both groups (59.4% and 65.6%, respectively). NPVs were also largely similar and highest for > 20 pack-years smoked for both groups (93.4 and 92.3%, respectively). The discriminative power represented by the AUC tended to be similar or slightly better for PLWH for all binary variables considered and was highest for > 20 pack-years of smoking [0.65; 95% confidence interval (CI) 0.58-0.72].
We also assessed the performance of respiratory symptoms in current smokers. The sensitivity of dyspnoea, sputum production, chronic cough and wheezing was 20.3 versus 12.9%, 43.1 versus 47.8%, 38.6 versus 34.8% and 61.0 versus 52.3% for PLWH and uninfected controls, respectively. Specificity was 89.8 versus 93.2%, 70.7 versus 79.0%, 80.0 versus 84.1% and 59.1 versus 65.0%, and AUC was 0.55 versus 0.53 (P = 0.50), 0.57 versus 0.63 (P = 0.11), 0.59 versus 0.60 (P = 0.98) and 0.60 versus 0.59 (P = 0.72), respectively. Figure 1 depicts the ROC plot for the combination of five variables that was associated with slightly higher AUC compared with the binary predictors alone. Thus, for PLWH, the AUC was 0.71 (95% CI 0.63-0.79) and for uninfected controls it was 0.65 (95% CI 0.63-0.68) (P = 0.06). Redefining the criteria for airflow limitation (from LLN to GOLD II disease) resulted in a higher AUC [i.e. 0.77 (95% CI 0.69-0.85) and 0.77 (95% CI 0.75-0.80), respectively; P = 0.98].
Discussion
Establishing a COPD diagnosis is important in order to initiate adequate risk factor modifications and potentially therapy. However, establishing a diagnosis in PLWH may be impeded by competing risk factors and respiratory symptoms caused by other infectious and noninfectious respiratory diseases in the population. We showed that the diagnostic performance of respiratory risk factors and symptoms (and a combination of these) in PLWH was relatively poor in discriminating airflow limitation but largely comparable to that in uninfected individuals.
To our knowledge, no other studies have compared the diagnostic performances of clinical characteristics in PLWH and uninfected controls. However, the multicentre Lung-HIV consortium evaluated the diagnostic performance of clinical characteristics in PLWH for detection of any abnormal spirometry pattern [defined as obstructive (FEV 1 /FVC < 0.7) and restricted (FEV 1 /FVC ≥ 0.7 and FVC < 80% predicted)] [13] . That study also found poor diagnostic performance of all binary predictors but slightly lower AUC values than in the present study. Our data confirm these findings and show that the diagnostic performances of binary predictors are, however, similar or potentially better than in uninfected individuals. The authors of the Lung-HIV consortium study argued that screening with spirometry could potentially be warranted as a consequence of a high prevalence of airflow limitation and poor predictive capability of respiratory symptoms in PLWH [13] . However, no study performed in PLWH has directly assessed the effects of spirometry screening for COPD on morbidity, mortality, or patientreported outcomes. Thus, clinical guidelines in PLWH still have to rely on findings from the general population. Spirometry screening in the general population has been reviewed by the UK National Screening Committee [7] and by the USPSTF [8] and both institutions recommended against the use of spirometry screening. However, the importance of spirometry in establishing the diagnosis of COPD should not be undermined and spirometry is likely to be underutilized in many HIV settings, especially in resource-limited settings. Moreover, screening spirometry as part of a smoking cessation strategy may positively influence quit rates [14] .
A number of studies in the general population have evaluated and externally validated combinations of risk factors and/or symptom-based questionnaires for COPD [11, [15] [16] [17] . We additionally assessed a simple combination of five binary items (i.e. age ≥ 50 years, wheezing, dyspnoea, sputum production, and cumulative smoking for ≥ 20 years) as these were associated with the highest AUC (0.72) in a previous study [11] . The combination of these items yielded a similar and acceptable AUC (0.71) in PLWH but slightly lower AUC (0.65) in uninfected controls.
In conclusion, our findings indicate that active casefinding based on respiratory risk factors and symptoms, as recommended in the general population [2] , is likely to have at least the same diagnostic power in PLWH. Future studies should compare binary and weighted scores (potentially including HIV-associated biomarkers of inflammation, immune activation and microbial translocation) for early detection of COPD in PLWH. Airflow limitation defined by FEV 1 /FVC < 0.7 and FEV 1 < 80% predicted (GOLD disease II). P = 0.98. The ROC is shown for the sum (1 = yes, 0 = no) of five different dichotomized items (i.e. age ≥ 50 years, wheezing, dyspnoea, sputum production and ≥ 20 pack-years of smoking).
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